Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 7,864 matching trials from the live ClinicalTrials.gov search.

Filters: Minneapolis, Minnesota Clear all

Conditions: Spinal Cord Diseases, Spinal Cord Injuries, Neurodegenerative Disorders, Cerebrovascular Accident With Associated Sequelae
Interventions: Adaptive Indoor Rowing Seat, Paddle Sport adaptive seating system; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Cleveland, Ohio

Conditions: Tracheostomy, Caregiver Burden
Interventions: Trach Plus, Trach Me Home; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: La Jolla, California • Silver Spring, Maryland • Boston, Massachusetts + 3 more

Conditions: Partial Epilepsy
Interventions: 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 106
States / cities: Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more

Conditions: Thoracic Aortic Aneurysm
Interventions: Valiant Thoracic Stent Graft System; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 21 more

Conditions: Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Palbociclib, Letrozole, Fulvestrant, Questionnaire Administration, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 70 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 447
States / cities: Anchorage, Alaska • Kingman, Arizona • Arroyo Grande, California + 303 more

Conditions: Myocardial Infarction
Interventions: Post-conditioning; Procedure
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kava, Anxiety, Stress, Cancer, Depression, Sleep
Interventions: Kava, Placebo; Drug · Dietary Supplement
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: Ataluren, PLACEBO; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 19 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Docetaxel, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 482
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 309 more

Conditions: End Stage Renal Disease, End-Stage Kidney Disease, Kidney Transplantation, Esrd
Interventions: Kidney Offer Shared Decision Making; Behavioral
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 625
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more

Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions: Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 29 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 111
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more

Conditions: Aortic Valve Insufficiency, Aortic Valve Regurgitation, Aortic Valve Stenosis, Aortic Valve Incompetence
Interventions: Trifecta™ Valve; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Minneapolis, Minnesota • Rochester, Minnesota + 6 more

Conditions: Diabetes Mellitus
Interventions: Well-controlled diabetic (WC), Poorly controlled diabetics (PC); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Houston, Texas • Seattle, Washington

Conditions: Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
Interventions: Not listed
Lead sponsor: CardioDx; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Anchorage, Alaska • Palo Alto, California • Minneapolis, Minnesota + 5 more

Conditions: Neuroleptic-Induced Tremor
Interventions: Gabapentin; Drug
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stress
Interventions: Meditation; Behavioral
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 56
States / cities: Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more

Conditions: HIV Infections
Interventions: Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 96
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone, Olanzapine, Quetiapine, Aripiprazole; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more

Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions: ECMO support, PROSpect protocolized therapies; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 14 Days to 20 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine); Drug
Lead sponsor: GRADE Study Group; Other
Eligibility: 30 Years and older
Enrollment: 7,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more

Conditions: Multiple Myeloma
Interventions: Panobinostat, Bortezomib, Dexamethasone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 38
States / cities: Phoenix, Arizona • Anaheim, California • Concord, California + 34 more

Conditions: Severe Sepsis
Interventions: Drotrecogin alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more

Search by objective public record fields.

Optimization of Adaptive Rowing Seating

Boosting Resources for Tracheostomy Care at Home

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Valor II: The Valiant Thoracic Stent Graft System Clinical Study

Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

Post-conditioning to Reduce Infarct Size

Effect of Kava on Anxiety and Stress in Cancer Survivors

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Trifecta™ Long Term Follow-Up (LTFU) Study

Alveolar Bone Changes in Diabetes (ABCD) Study

Diagnostic Investigation of Sudden Cardiac Event Risk

Gabapentin for the Treatment of Neuroleptic-Induced Tremor

Stress Reduction for Busy Professionals

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)